Recent patient data surrounding this compound, specifically the 120mg formulation branded as ZPHC, suggest a considerable impact on body mass decrease and related metabolic conditions . Researchers posit that this innovative acting , targeting both GLP-1 and GIP receptors , has the potential to provide a noteworthy breakthrough in the management of